Welcome to our dedicated page for Intellia Therape SEC filings (Ticker: NTLA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Intellia Therapeutics, Inc. (NASDAQ: NTLA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including Current Reports on Form 8-K that detail material events in its clinical and corporate development. As a clinical-stage gene editing company, Intellia uses SEC filings to report key information about its CRISPR-based programs, financial results and significant regulatory interactions.
Recent 8-K filings furnished by Intellia describe positive Phase 1 and Phase 1/2 data for its investigational in vivo CRISPR therapies, nexiguran ziclumeran (nex-z) for transthyretin (ATTR) amyloidosis and lonvoguran ziclumeran (lonvo-z) for hereditary angioedema (HAE). These filings summarize trial designs, patient numbers, biomarker reductions, clinical outcome measures and safety observations over multi-year follow-up. Other 8-Ks discuss the initiation and status of global Phase 3 trials such as MAGNITUDE, MAGNITUDE-2 and HAELO, as well as the FDA’s clinical hold on the MAGNITUDE programs for nex-z.
Intellia also uses Form 8-K to furnish quarterly financial results, including collaboration revenue, research and development expenses, general and administrative expenses and cash, cash equivalents and marketable securities. Additional filings report equity inducement grants made under the company’s 2024 Inducement Plan pursuant to Nasdaq Listing Rule 5635(c)(4), and changes involving senior executives.
On Stock Titan, these SEC filings are updated in near real time from EDGAR and can be paired with AI-powered summaries that highlight the most important points in dense regulatory documents. Users can quickly understand the implications of Intellia’s 8-K disclosures, track the evolution of its nex-z and lonvo-z programs, and monitor material events that may affect NTLA’s risk profile and development timeline.
The Vanguard Group filed an amended Schedule 13G reporting beneficial ownership of 13,010,001 shares of Intellia Therapeutics Inc common stock, representing 11.23% of the class as of 12/31/2025.
Vanguard reports shared voting power over 864,210 shares and shared dispositive power over all 13,010,001 shares, with no sole voting or dispositive power. The filing states the shares are held in the ordinary course of business and not for the purpose of changing or influencing control of Intellia.
Vanguard also notes an internal realignment effective 01/12/2026, after which certain subsidiaries or business divisions that are deemed to have beneficial ownership may report their holdings separately, while continuing the same investment strategies.
Intellia Therapeutics reports that the U.S. FDA has removed the clinical hold on the investigational new drug application for its MAGNITUDE-2 Phase 3 trial of nexiguran ziclumeran ("nex-z") in patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN). The FDA had placed MAGNITUDE-2 and the related MAGNITUDE Phase 3 cardiomyopathy (ATTR-) trial on hold after a MAGNITUDE patient experienced Grade 4 liver transaminase elevations with increased total bilirubin and subsequently died, triggering protocol-defined pausing criteria. Intellia has now agreed with the FDA on study modifications and mitigation measures, including enhanced liver safety monitoring, and is working with investigators, ethics committees, regulators and other stakeholders to restart enrollment in MAGNITUDE-2.
The FDA clinical hold on the MAGNITUDE Phase 3 trial in ATTR- remains in place, and Intellia’s engagement with the agency on a path forward for that program is ongoing. The company plans to provide an update once alignment with the FDA is reached on next steps for the cardiomyopathy trial.
Intellia Therapeutics reported safety updates from its Phase 3 MAGNITUDE and MAGNITUDE-2 trials of nexiguran ziclumeran ("nex-z") for transthyretin amyloidosis. A previously disclosed patient in MAGNITUDE experienced Grade 4 liver transaminase elevations and increased bilirubin, triggering a protocol-defined pause, and the FDA placed a clinical hold on the nex-z Phase 3 programs. The patient later died on November 5, 2025, with the principal investigator attributing the death to septic shock secondary to a perforated duodenal ulcer, with a clinical course that included acute liver injury treated with corticosteroids and supported by autopsy findings.
More than 650 patients with ATTR-CM are enrolled in MAGNITUDE and 47 patients with hereditary ATTRv-PN are enrolled in MAGNITUDE-2. Grade 4 liver transaminase elevations have occurred in less than one percent of MAGNITUDE patients, with no such events in MAGNITUDE-2, and all cases except the fatal one resolved within weeks without reported clinical sequelae. The company also updated its corporate presentation for investor and analyst meetings and plans to provide a further update after finalizing a path forward for nex-z with regulators.
Intellia Therapeutics, Inc. President and CEO John M. Leonard, who is also a director, reported a mandatory sell-to-cover stock transaction. On January 5, 2026, he sold 34,146 shares of common stock at $9.21 per share to cover tax withholding obligations arising from the vesting of restricted stock units on January 1, 2026. The filing states this was not a voluntary trade. After this transaction, Leonard beneficially owned 1,013,339 common shares directly and an additional 58,415 common shares indirectly held by the John M. Leonard 2015 Irrevocable Trust.
Intellia Therapeutics EVP and Chief Scientific Officer Birgit C. Schultes reported a mandatory tax-related stock sale. On January 5, 2026, she sold 8,508 shares of Intellia Therapeutics common stock at a price of $9.21 per share. A footnote explains this was a required “sell-to-cover” transaction to satisfy tax withholding obligations upon the vesting of restricted stock units on January 1, 2026, and not a voluntary trade. Following this transaction, she beneficially owned 98,533 shares of Intellia common stock, which include 925 and 932 shares acquired under the company’s 2016 Employee Stock Purchase Plan on June 30, 2025 and December 31, 2025, respectively.
Intellia Therapeutics executive James Basta reported a tax-related stock sale. On January 5, 2026, he sold 10,397 shares of Intellia Therapeutics common stock at a price of $9.21 per share. According to the filing, this was a mandatory “sell-to-cover” transaction to satisfy his tax withholding obligation from restricted stock units that vested on January 1, 2026, and it is explicitly described as not a voluntary trade. After this transaction, he beneficially owned 101,528 shares of Intellia common stock directly.
Intellia Therapeutics, Inc. director Fred E. Cohen reported an open market purchase of the company’s common stock. On January 5, 2026, he bought 150,000 shares of common stock at a weighted average price of $9.35 per share, coded as a purchase transaction.
According to the filing, these shares were acquired in multiple trades at prices ranging from $9.13 to $9.68. Following this transaction, Cohen beneficially owns 207,453 shares of Intellia Therapeutics common stock held directly.
Intellia Therapeutics EVP and Chief Medical Officer David Lebwohl reported a sale of common stock that was carried out solely to cover taxes on recently vested restricted stock units. On January 5, 2026, he sold 11,903 shares of Intellia Therapeutics common stock at $9.21 per share in a mandatory "sell-to-cover" transaction tied to RSUs that vested on January 1, 2026. After this transaction, Lebwohl beneficially owned 121,249 shares of Intellia common stock. This total includes 1,022 shares and 1,264 shares that were previously acquired through the company’s 2016 Employee Stock Purchase Plan on June 30, 2025 and December 31, 2025, respectively.
Intellia Therapeutics executive Eliana Clark reported an automatic share sale related to taxes. A Form 4 shows that on January 5, 2026, the EVP and Chief Technical Officer sold 9,515 shares of Intellia Therapeutics common stock at $9.21 per share. The filing explains this was a mandatory “sell-to-cover” transaction to satisfy her tax withholding obligation upon the vesting of restricted stock units on January 1, 2026, and does not represent a volitional trade by the reporting person.
After this transaction, she beneficially owns 87,118 shares of Intellia common stock, including 1,264 shares acquired under the company’s 2016 Employee Stock Purchase Plan on December 31, 2025.
Intellia Therapeutics EVP and CFO Edward J. Dulac III reported an automatic sale of company stock. On January 5, 2026, he sold 6,379 shares of Intellia Therapeutics common stock at a price of $9.21 per share. According to the disclosure, this was a mandatory “sell-to-cover” transaction to satisfy tax withholding obligations tied to restricted stock units that vested on January 1, 2026, and it is described as not being a voluntary trade by the executive. After this transaction, he beneficially owns 99,683 shares of Intellia Therapeutics common stock directly.
FAQ
What is the current stock price of Intellia Therape (NTLA)?
What is the market cap of Intellia Therape (NTLA)?
